JP Morgan Chase
INKT icon

JP Morgan Chase’s MiNK Therapeutics INKT Stock Holding History

JP Morgan Chase’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$107 Hold
9
– – ﹤0.01% 7536
2026
Q1 		$95 Hold
9
– – ﹤0.01% 7315
2025
Q4 		$100 Hold
9
– – ﹤0.01% 7213
2025
Q3 		$126 Sell
9
-3
-25% -$48 ﹤0.01% 7151
2025
Q2 		$89 Sell
12
-18
-60% -$135 ﹤0.01% 6855
2025
Q1 		$259 Sell
30
-3
-9% -$27 ﹤0.01% 6769
2024
Q4 		$227 Buy
33
+20
+154% +$136 ﹤0.01% 6899
2024
Q3 		$97 Buy
13
+2
+18% +$17 ﹤0.01% 7007
2024
Q2 		$102 Hold
11
– – ﹤0.01% 6887
2024
Q1 		$97 Hold
11
– – ﹤0.01% 6907
2023
Q4 		$115 Hold
11
– – ﹤0.01% 7108
2023
Q3 		$125 Hold
11
– – ﹤0.01% 6889
2023
Q2 		$225 Buy
+11
New +$220 ﹤0.01% 6622
2022
Q3 		– Sell
-25
Closed – – 6644
2022
Q2 		$0 Sell
25
-69
-73% -$1.3K ﹤0.01% 6666
2022
Q1 		$2K Buy
+94
New +$2.82K ﹤0.01% 6422

Other funds holding INKT

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 29.84% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

JP Morgan Chase's INKT Position: Q2 2026 in Review

JP Morgan Chase held its MiNK Therapeutics (INKT) position steady in Q2 2026 at 9 shares worth $107. The position accounts for ﹤0.01% of the portfolio, ranked #7536.

JP Morgan Chase first reported a position in INKT in Q1 2022 and has held it in 15 quarters since. The position peaked at $2K in Q1 2022. 27 funds tracked by Wall St. Rank hold INKT as of Q2 2026.

  • JP Morgan Chase held 9 shares of MiNK Therapeutics worth $107 as of Q2 2026.
  • JP Morgan Chase left its MiNK Therapeutics share count unchanged in Q2 2026.
  • MiNK Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #7536 holding.
  • JP Morgan Chase first reported a position in MiNK Therapeutics in Q1 2022 and has held it in 15 quarters since.
  • JP Morgan Chase's MiNK Therapeutics position peaked at $2K in Q1 2022.
  • 27 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.